All Metals Fabricating Strengthens Position as Manufacturing Leader with Addition of Kitamura Supercell-300G

All Metals Fabricating is proud to announce the addition of a state-of-the-artKitamura Supercell-300G 5-Axis Horizontal Machining Centerto their CNC machining department. This investment significantly expands the company's machining capabilities and lights-out capacity, cementing their status as a leader in precision manufacturing. https://mma.prnewswire.com/media/2813758/All_Metals_Fabricating_Supercell_300G.jpg All Metals is proud to announce the addition of a Kitamura Supercell-300G 5-Axis […]

PHX Energy Announces Third Quarter Results & 2026 Capital Expenditure Budget

(TSX:PHX), CALGARY, Alberta, Nov. 04, 2025 (GLOBE NEWSWIRE) — Third Quarter Highlights For the three-month period ended September 30, 2025, PHX Energy generated consolidated revenue of $164.3 million, which is 2 percent higher than the $160.6 million generated in the third quarter of 2024. Consolidated revenue in the 2025-quarter included $11.9 million of motor rental

Urgently Announces Third Quarter 2025 Earnings Release Date and Conference Call

(NASDAQ:ULY), ASHBURN, Va., Nov. 04, 2025 (GLOBE NEWSWIRE) — Urgent.ly Inc. (Nasdaq: ULY) (“Urgently”), a U.S.-based leading provider of digital roadside and mobility assistance technology and services, today announced the date for the release of its third quarter 2025 financial results. Urgently will host a conference call on Wednesday, November 12, 2025, at 5:00 p.m.

PHX Energy Announces Third Quarter Results & 2026 Capital Expenditure Budget

PHX Energy Announces Third Quarter Results & 2026 Capital Expenditure Budget GlobeNewswire November 04, 2025 CALGARY, Alberta, Nov. 04, 2025 (GLOBE NEWSWIRE) — Third Quarter Highlights For the three-month period ended September 30, 2025, PHX Energy generated consolidated revenue of $164.3 million, which is 2 percent higher than the $160.6 million generated in the third

Urgently Announces Third Quarter 2025 Earnings Release Date and Conference Call

Urgently Announces Third Quarter 2025 Earnings Release Date and Conference Call GlobeNewswire November 04, 2025 ASHBURN, Va., Nov. 04, 2025 (GLOBE NEWSWIRE) — Urgent.ly Inc. (Nasdaq: ULY) (“Urgently”), a U.S.-based leading provider of digital roadside and mobility assistance technology and services, today announced the date for the release of its third quarter 2025 financial results.

NexPoint Real Estate Finance, Inc. Launches $200 Million Continuous Offering of 8.00% Series C Cumulative Redeemable Preferred Stock

NexPoint Real Estate Finance, Inc. (NYSE: NREF) (“NREF” or the “Company”) announced today the launch of a continuous public offering of up to 8,000,000 shares of its newly designated 8.00% Series C Cumulative Redeemable Preferred Stock (the “Series C Preferred Stock”) at a price to the public of $25.00 per share, for gross proceeds of

Investors SueWallSt as Fluor Corporation Faces Securities Fraud Allegations

NEW YORK, NY / ACCESS Newswire / November 4, 2025 / – SueWallSt: Class Action Filed Against Fluor Corporation – Contact Levi & Korsinsky A Class Action lawsuit was filed on behalf of investors who lost money as a result of alleged securities fraud between February 18, 2025 and July 31, 2025. If you suffered

Imperial Reports Third Quarter 2025 Financial Results

(TSX:III), VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) — Imperial Metals Corporation (the “Company” or “Imperial”) (TSX:III) reports financial results for the three and nine months ended September 30, 2025. QUARTER HIGHLIGHTS “Operationally, the third quarter was aligned with guidance, driven largely by higher throughput at Mount Polley and higher copper and gold grades

Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

Encore pivotal efficacy and safety data from the ARROS-1 trial also to be presented during poster session Nuvalent, Inc.(Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creatingpreciselytargeted therapies for clinically proven kinase targets in cancer, today announced the first presentation of patient-reported outcomes data from the Phase 2 portion of the ARROS-1 Phase 1/2 clinical

Scroll to Top